JP2006305390A5 - - Google Patents

Download PDF

Info

Publication number
JP2006305390A5
JP2006305390A5 JP2006223635A JP2006223635A JP2006305390A5 JP 2006305390 A5 JP2006305390 A5 JP 2006305390A5 JP 2006223635 A JP2006223635 A JP 2006223635A JP 2006223635 A JP2006223635 A JP 2006223635A JP 2006305390 A5 JP2006305390 A5 JP 2006305390A5
Authority
JP
Japan
Prior art keywords
metered dose
inhalation formulation
dose inhalation
formulation
metered
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2006223635A
Other languages
English (en)
Japanese (ja)
Other versions
JP2006305390A (ja
Filing date
Publication date
Application filed filed Critical
Publication of JP2006305390A publication Critical patent/JP2006305390A/ja
Publication of JP2006305390A5 publication Critical patent/JP2006305390A5/ja
Pending legal-status Critical Current

Links

JP2006223635A 2002-08-27 2006-08-18 定量吸入処方物を産生するためのプロセス Pending JP2006305390A (ja)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US40612702P 2002-08-27 2002-08-27
US42243602P 2002-10-30 2002-10-30

Related Parent Applications (1)

Application Number Title Priority Date Filing Date
JP2004532972A Division JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス

Publications (2)

Publication Number Publication Date
JP2006305390A JP2006305390A (ja) 2006-11-09
JP2006305390A5 true JP2006305390A5 (enExample) 2009-12-03

Family

ID=31981380

Family Applications (3)

Application Number Title Priority Date Filing Date
JP2004532972A Expired - Fee Related JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス
JP2006223635A Pending JP2006305390A (ja) 2002-08-27 2006-08-18 定量吸入処方物を産生するためのプロセス
JP2010229135A Withdrawn JP2011046726A (ja) 2002-08-27 2010-10-08 定量吸入処方物を産生するためのプロセス

Family Applications Before (1)

Application Number Title Priority Date Filing Date
JP2004532972A Expired - Fee Related JP4679901B2 (ja) 2002-08-27 2003-08-26 定量吸入処方物を産生するためのプロセス

Family Applications After (1)

Application Number Title Priority Date Filing Date
JP2010229135A Withdrawn JP2011046726A (ja) 2002-08-27 2010-10-08 定量吸入処方物を産生するためのプロセス

Country Status (14)

Country Link
US (3) US20040042973A1 (enExample)
EP (2) EP1878664B1 (enExample)
JP (3) JP4679901B2 (enExample)
AT (2) ATE384001T1 (enExample)
AU (1) AU2003265639A1 (enExample)
CA (1) CA2495875C (enExample)
CY (1) CY1107376T1 (enExample)
DE (2) DE60336602D1 (enExample)
DK (1) DK1542904T3 (enExample)
ES (1) ES2297262T3 (enExample)
MX (1) MXPA05002248A (enExample)
PT (1) PT1542904E (enExample)
SI (1) SI1542904T1 (enExample)
WO (1) WO2004020289A1 (enExample)

Families Citing this family (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB0207906D0 (en) 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
ATE353231T1 (de) * 2002-08-23 2007-02-15 Schering Corp Pharmazeutische zusammensetzungen
JP2007509147A (ja) * 2003-10-20 2007-04-12 シェーリング　コーポレイション 薬学的エアロゾル組成物
SE0401408D0 (sv) * 2004-06-02 2004-06-02 Astrazeneca Ab Diameter measuring device
EP1811981B1 (en) * 2004-10-12 2008-08-13 Merck Generics (UK) Limited Process for the preparation of suspension aerosol formulations, wherein the particles are formed by precipitation inside an aerosol canister
US20070099883A1 (en) * 2005-10-07 2007-05-03 Cheryl Lynn Calis Anhydrous mometasone furoate formulation
EP2083798A1 (en) * 2006-10-19 2009-08-05 Cipla Limited Pharmaceutical compositions and nasal spray incorporating anhydrous mometasone furoate
AU2007346134A1 (en) 2007-02-09 2008-08-14 Merck Sharp & Dohme Corp. Stable pharmaceutical drug aerosols
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products
HUE027718T2 (en) 2009-05-12 2016-10-28 Galenica Ab Oil-in-water emulsion containing mometasone and propylene glycol
US20120128736A1 (en) * 2009-05-12 2012-05-24 Galenica Ab Oil-in-water emulsion of mometasone
US20130112194A1 (en) * 2010-02-10 2013-05-09 Simon Christopher Berry Process for providing a filled canister for an inhaler
AU2015200276B2 (en) * 2010-02-10 2016-01-21 Astrazeneca Uk Limited A filled canister for an inhaler
CN107626019A (zh) * 2016-07-18 2018-01-26 卓效医疗有限公司 手持式喷雾器
CN107951893B (zh) * 2016-10-18 2022-04-26 天津金耀集团有限公司 一种糠酸莫米松粉吸入剂组合物

Family Cites Families (24)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3592319A (en) * 1968-10-28 1971-07-13 Roy S Rousseau Article feed control
US3835898A (en) * 1972-11-13 1974-09-17 Kartridg Pak Co Remotely adjustable filling head
US4793461A (en) * 1987-02-26 1988-12-27 The Kartridg Pak Co. Container feed apparatus
US5143260A (en) * 1990-06-05 1992-09-01 Nozone Dispenser Systems, Inc. Aerosol adapter clamp and power system
US5182097A (en) * 1991-02-14 1993-01-26 Virginia Commonwealth University Formulations for delivery of drugs by metered dose inhalers with reduced or no chlorofluorocarbon content
HUT67449A (en) * 1991-06-10 1995-04-28 Schering Corp Aerosol formulations containing 1,1,1,2,3,3,3-heptafluoropropane
CA2111003A1 (en) * 1991-06-10 1992-12-23 Julianne Fassberg Non-chlorofluorocarbon aerosol formulations
US5275212A (en) * 1993-02-24 1994-01-04 Minnesota Mining And Manufacturing Company Aerosol filling method
GB9612297D0 (en) * 1996-06-11 1996-08-14 Minnesota Mining & Mfg Medicinal aerosol formulations
US5698161A (en) 1996-08-26 1997-12-16 Michigan Critical Care Consultants, Inc. Hollow, multi-dimensional array membrane
DK0927037T3 (da) * 1996-08-29 2001-09-24 Schering Corp Aerosolformuleringer af mometason-furoat uden chlorfluorcarbonhydrider
US6068832A (en) * 1996-08-29 2000-05-30 Schering Corporation Chlorofluorocarbon-free mometasone furoate aerosol formulations
US20060165606A1 (en) * 1997-09-29 2006-07-27 Nektar Therapeutics Pulmonary delivery particles comprising water insoluble or crystalline active agents
US6004537A (en) * 1998-12-18 1999-12-21 Baker Norton Pharmaceuticals, Inc. Pharmaceutical solution aerosol formulations containing fluoroalkanes, budesonide and formoterol
GB9904919D0 (en) * 1999-03-03 1999-04-28 Novartis Ag Organic compounds
WO2001047493A1 (en) * 1999-12-24 2001-07-05 Glaxo Group Limited Pharmaceutical aerosol formulation of salmeterol and fluticasone propionate
EP1311294A2 (en) * 2000-08-04 2003-05-21 Longwood Pharmaceutical Research, Inc. Formulations of mometasone and a bronchodilator for pulmonary administration
ITMI20010428A1 (it) * 2001-03-02 2002-09-02 Chemo Breath S A Composizioni ad uso inalatorio a base di formoterolo
AR036358A1 (es) * 2001-08-28 2004-09-01 Schering Corp Un inhalador de dosis medidas que contiene una formulacion de suspension en aerosol para inhalacion, un proceso para la produccion de la formulacion, el producto y el uso de una formulacion para la manufactura de un medicamento de asma
GB0207906D0 (en) * 2002-04-05 2002-05-15 3M Innovative Properties Co Formoterol and mometasone aerosol formulations
ATE353231T1 (de) * 2002-08-23 2007-02-15 Schering Corp Pharmazeutische zusammensetzungen
JP2007509147A (ja) * 2003-10-20 2007-04-12 シェーリング　コーポレイション 薬学的エアロゾル組成物
EP1981545A2 (en) * 2006-02-09 2008-10-22 Schering Corporation Pharmaceutical formulations
US20080253970A1 (en) * 2007-02-09 2008-10-16 Schering Corporation Stable Pharmaceutical Drug Products

Similar Documents

Publication Publication Date Title
IL209499A (en) Human monoclonal antibody against influenza virus a, Pharmaceutical preparations containing it and its use in drug preparation
DK1907037T3 (da) Medikamentdispenser.
EG25113A (en) Inhaler device counter.
IL195488A (en) Compounds, pharmaceuticals containing them and their uses
JP2006213929A5 (enExample)
IL203915A (en) Annotations of 2-Benzylphenyl-6-Hydroxymethyl-Tetrahydro-2 H-Pyrene-3,4,5-Triol
IL211400A0 (en) Substituted aminoindanes and analogs thereof, and the pharmaceutical use thereof
BRPI0810646A2 (pt) " compostos farmacêuticos ".
ZA200805953B (en) Inhaler with breath actuated dose counter
ZA200802272B (en) Novel dosage formulation
ATE493119T1 (de) Pharmazeutische zusammensetzung
JP2006305390A5 (enExample)
EP1987825A4 (en) PHARMACEUTICAL COMPOSITION COMPRISING OSELTAMIVIR PHOSPHATE
EP2193795A4 (en) AQUEOUS PHARMACEUTICAL COMPOSITION CONTAINING LATANOPROST
IL209304A0 (en) Peptides, peptidomimetics and derivatives thereof, the manufacturing thereof as well as their use for preparing a therapeutically and/or preventively active pharmaceutical composition
GB2452696B (en) 3-(2',2'-dimethylpropanoylamino)-tetrahydropyridin-2-one and its use in pharmaceutical compositions
IL202359A0 (en) 17??-cyano-19-nor-androst-4-ene derivative, use thereof and medicaments containing said derivative
PL2217255T3 (pl) Zastosowanie fitoekdyzonów do wytwarzania kompozycji do wpływania na zespół metaboliczny
EP1916251A4 (en) ERIANINE SALTS, PROCESSES FOR THEIR PREPARATION AND PHARMACEUTICAL COMPOSITIONS CONTAINING THE SAME
ZA200806949B (en) Medicinal formulation for the treatment for hepatitis C
ITFI20080016A1 (it) Formulazioni farmaceutiche orali contenenti gliclazide.
JP2008533990A5 (enExample)
EP2305304A4 (en) IMMUNOSTIMULATOR WITH EP1 AGONIST
EP2192122A4 (en) DITHIOLOPYRROLON COMPOUNDS, THEIR PREPARATION AND THEIR USE
IL202325A0 (en) 17??-cyano-19-androst-4-ene derivative, use thereof and medicaments containing said derivative